Enveric Biosciences, Inc.

Our CEO, Joseph Tucker, PhD, comments on the Company’s new U.S. patent covering its EVM301 Series of molecules, including lead candidate EB-003, being developed as a potential treatment for mental health disorders. For more info: bit.ly/4tjrD87 $ENVB

Enveric has received a U.S. Patent from the USPTO for its EVM301 Series including lead candidate EB-003. The patent strengthens Enveric’s EVM301 IP portfolio of potential neuroplastogenic, non-hallucinogenic molecules for neuropsychiatric treatments. bit.ly/4tjrD87 $ENVB

Enveric today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025. See it here: bit.ly/4bCMVrz $ENVB

Our CEO, Joseph Tucker, Ph.D., comments on the registration of five trademarks that supports Enveric’s branding strategy for its future products. Learn more: bit.ly/4buehyK $ENVB

Enveric Biosciences announced that the Canadian Intellectual Property Office has registered five of the Company’s trademarks, including its house marks, Enveric and Enveric Biosciences. For more details: bit.ly/4buehyK $ENVB

Our CEO, Joseph Tucker, sat down w/ Drug Discovery Online to discuss the shift in neuropsychiatric drug development toward neuroplastogens & Enveric’s EB-003, which has been found to activate Gq- & β-arrestin signaling pathways linked to therapeutic-related brain biology. bit.ly/46Ru89a $ENVB

.@PharmaTech_News details how the withdrawal of the Post Grant Review petition against Enveric’s ’276 patent reframes the neuroplastogen race & reinforces its positioning as a company w/ a strong IP foundation in next-generation, psychedelic-inspired drug development. bit.ly/4aV0TTQ $ENVB

Enveric’s CEO, Joseph Tucker, explains the potential benefits of EB-003's dual mechanism that selectively engages both the 5-HT2A and 5-HT1B receptors to promote neuroplasticity without triggering unwanted effects. Learn more in @DrugDiscovNews: bit.ly/3MQCUgH $ENVB

.@Medium details new insight into how Enveric's next-generation neuroplastogens, EB-003, may separate the therapeutic benefits of psychedelics from hallucinogenic effects, potentially making treatment for neuropsychiatric disorders more accessible. bit.ly/3Mowqpk $ENVB

.@microdosehq details the withdrawal of a Post Grant Review petition filed against Enveric’s ‘276 patent, reinforcing the strength of the Company’s intellectual property estate for its pipeline of next-generation, psychedelic-inspired therapeutics. bit.ly/3MM7ZlO $ENVB

Pharma Device News highlights the differentiated profile of Enveric’s EB-003, with preclinical data demonstrating a dual-pathway mechanism that activates therapeutic signaling downstream of the 5-HT2A receptor without inducing hallucinations. bit.ly/3OMcI7z $ENVB

Our CEO, Joseph Tucker, Ph.D., comments on the withdrawal of Gilgamesh's petition against Enveric’s ‘276 patent. For more details, visit: bit.ly/4scaxZv $ENVB

Enveric has announced that the Post-Grant Review (PGR) petition filed by Gilgamesh against Enveric’s ‘276 patent has been withdrawn. As a result of this action, there are no remaining challenges currently pending against Enveric’s patent. Learn more: bit.ly/4scaxZv $ENVB

A recent study published in Nature used BRET assays to dissect 5-HT2A signaling mechanisms. The findings suggest that therapeutic effects & hallucinations may arise from separable intracellular mechanisms, underscoring the potential of non-hallucinogenic neuroplastogens. bit.ly/470BZB4 $ENVB

New mechanistic findings from Enveric’s BRET assay data evaluating its lead candidate, EB-003, were highlighted by @microdosehq, reinforcing its potential as a non-hallucinogenic neuroplastogen designed to support more scalable treatment paradigms. bit.ly/4rqhRR8 $ENVB

Findings from a recent independent Nature study indicate that therapeutic benefit & hallucinations may arise from distinct intracellular pathways, strengthening confidence in the scientific foundation of Enveric's neuroplastogen, EB-003. bit.ly/3ZHJNnB $ENVB

.@DrugDiscovNews highlights Enveric's EB-003 as part of the next wave of psychedelics that are focused on separating therapeutic neuroplasticity from hallucinations to create drugs that are scalable, easier to administer, & reduce treatment burden. bit.ly/3MQCUgH $ENVB

Our CEO, Joseph Tucker, comments on receptor engagement assay data for EB-003 demonstrating biologically relevant engagement of both Gq and β-arrestin pathways downstream of 5-HT A. Learn more: bit.ly/3ZHJNnB $ENVB

Enveric Biosciences announced new mechanistic data demonstrating that EB-003 activates both Gq- & β-arrestin-mediated signaling downstream of the 5-HT A receptor, pathways linked in peer-reviewed studies to antidepressant & anxiolytic effects. bit.ly/3ZHJNnB $ENVB

.@microdosehq details a recent study suggesting psilocybin’s durability may involve the serotonin 1B receptor, not just 2A. Enveric’s EB-003 targets both 5-HT1B and 5-HT2A, positioning it as a differentiated candidate for the treatment of depression & anxiety. bit.ly/4aN7sJl $ENVB